Alkermes plc (ALKS) : During the past 4 weeks, traders have been relatively bearish on Alkermes plc (ALKS), hence the stock is down -11.2% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.86% relative to the S&P 500. The 4-week change in the price of the stock is -10.86% and the stock has fallen -4.89% in the past 1 week.
Alkermes plc is up 3.28% in the last 3-month period. Year-to-Date the stock performance stands at -44.08%. The stock has recorded a 20-day Moving Average of 8.04% and the 50-Day Moving Average is 3.99%.
Alkermes plc (NASDAQ:ALKS): The stock opened at $45.01 on Friday but the bulls could not build on the opening and the stock topped out at $45.01 for the day. The stock traded down to $43.86 during the day, due to lack of any buying support eventually closed down at $44.39 with a loss of -1.90% for the day. The stock had closed at $45.25 on the previous day. The total traded volume was 662,850 shares.
Also, In a research note released to the investors, Barclays maintains its rating on Alkermes plc (NASDAQ:ALKS).The analysts at the brokerage house have a current rating of Overweight on the shares. In a recent information released to the investors, Barclays raises the new price target from $65 per share to $66 per share. The rating by the firm was issued on July 29, 2016.
Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders, such as addiction, schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil, ALKS 5461, ALKS 3831, ALKS 8700 and RDB 1419. The Companys main marketed products include RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, AMPYRA/FAMPYRA, BYDUREON and VIVITROL.